Skip to main content
NCBI home page
Journal of Clinical Pathology logoLink to Journal of Clinical Pathology
. 1997 Aug;50(8):661–663. doi: 10.1136/jcp.50.8.661

Immunoexpression of c-erbB-2 and p53 in benign and malignant salivary neoplasms with myoepithelial differentiation.

J C Rosa 1, A Félix 1, I Fonseca 1, J Soares 1
PMCID: PMC500110  PMID: 9301549

Abstract

AIM: To evaluate whether the immunoexpression of c-erbB-2 and p53 is involved in the pathogenesis and progression of salivary tumours with myoepithelial differentiation. METHODS: 233 tumours from 211 patients were studied. These included 76 primary and 24 recurrent adenocarcinomas (polymorphous low grade adenocarcinoma, 13; epithelial-myoepithelial carcinoma, 19; adenoid cystic carcinoma, 56; and basal cell adenocarcinoma, 12) and 133 pleomorphic adenomas and myoepitheliomas, 96 being primary and the remaining recurrent tumours. All cases were formalin fixed and paraffin wax embedded. A StrepABC peroxidase method and polyclonal c-erbB-2 and p53 specific antisera were used. RESULTS: Cell membrane staining of c-erbB-2 was not found in any benign or malignant tumour. There was p53 protein accumulation in one primary and one recurrent pleomorphic adenoma and in 10 adenocarcinomas (polymorphous low grade adenocarcinoma, one; epithelial-myoepithelial carcinoma, one; adenoid cystic carcinoma, five; and basal cell adenocarcinoma, three), three of them being recurrences. CONCLUSIONS: The c-erbB-2 and p53 proteins are not involved in the pathogenesis of pleomorphic adenoma and myoepithelioma and do not constitute biomarkers in assessing the risk of recurrence. c-erbB-2 is not involved in the genesis of low grade salivary neoplasia with myoepithelial differentiation. The percentage of this type of neoplasia with p53 accumulation is low (10%) and does not appear to be related to tumour recurrence.

Full text

PDF
661

Images in this article

662Image
on p.662

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Cho K. J., el-Naggar A. K., Ordonez N. G., Luna M. A., Austin J., Batsakis J. G. Epithelial-myoepithelial carcinoma of salivary glands. A clinicopathologic, DNA flow cytometric, and immunohistochemical study of Ki-67 and HER-2/neu oncogene. Am J Clin Pathol. 1995 Apr;103(4):432–437. doi: 10.1093/ajcp/103.4.432. [DOI] [PubMed] [Google Scholar]
  2. Deguchi H., Hamano H., Hayashi Y. c-myc, ras p21 and p53 expression in pleomorphic adenoma and its malignant form of the human salivary glands. Acta Pathol Jpn. 1993 Jul-Aug;43(7-8):413–422. doi: 10.1111/j.1440-1827.1993.tb01152.x. [DOI] [PubMed] [Google Scholar]
  3. Felix A., El-Naggar A. K., Press M. F., Ordonez N. G., Fonseca I., Tucker S. L., Luna M. A., Batsakis J. G. Prognostic significance of biomarkers (c-erbB-2, p53, proliferating cell nuclear antigen, and DNA content) in salivary duct carcinoma. Hum Pathol. 1996 Jun;27(6):561–566. doi: 10.1016/s0046-8177(96)90162-8. [DOI] [PubMed] [Google Scholar]
  4. Gallo O., Franchi A., Bianchi S., Boddi V., Giannelli E., Alajmo E. p53 oncoprotein expression in parotid gland carcinoma is associated with clinical outcome. Cancer. 1995 Apr 15;75(8):2037–2044. doi: 10.1002/1097-0142(19950415)75:8<2037::aid-cncr2820750802>3.0.co;2-v. [DOI] [PubMed] [Google Scholar]
  5. Gnepp D. R. Malignant mixed tumors of the salivary glands: a review. Pathol Annu. 1993;28(Pt 1):279–328. [PubMed] [Google Scholar]
  6. Hellquist H. B., Karlsson M. G., Nilsson C. Salivary duct carcinoma--a highly aggressive salivary gland tumour with overexpression of c-erbB-2. J Pathol. 1994 Jan;172(1):35–44. doi: 10.1002/path.1711720108. [DOI] [PubMed] [Google Scholar]
  7. Ishii K., Nakajima T. Evaluation of malignant grade of salivary gland tumors: studies by cytofluorometric nuclear DNA analysis, histochemistry for nucleolar organizer regions and immunohistochemistry for p53. Pathol Int. 1994 Apr;44(4):287–296. doi: 10.1111/j.1440-1827.1994.tb03366.x. [DOI] [PubMed] [Google Scholar]
  8. Kamio N. Coexpression of p53 and c-erbB-2 proteins is associated with histological type, tumour stage, and cell proliferation in malignant salivary gland tumours. Virchows Arch. 1996 May;428(2):75–83. doi: 10.1007/BF00193934. [DOI] [PubMed] [Google Scholar]
  9. Kastan M. B., Onyekwere O., Sidransky D., Vogelstein B., Craig R. W. Participation of p53 protein in the cellular response to DNA damage. Cancer Res. 1991 Dec 1;51(23 Pt 1):6304–6311. [PubMed] [Google Scholar]
  10. Kernohan N. M., Blessing K., King G., Corbett I. P., Miller I. D. Expression of c-erbB-2 oncoprotein in salivary gland tumours: an immunohistochemical study. J Pathol. 1991 Jan;163(1):77–80. doi: 10.1002/path.1711630113. [DOI] [PubMed] [Google Scholar]
  11. Kärjä V., Syrjänen S., Kataja V., Syrjänen K. c-erbB-2 oncogene expression in salivary gland tumours. ORL J Otorhinolaryngol Relat Spec. 1994 Jul-Aug;56(4):206–212. doi: 10.1159/000276657. [DOI] [PubMed] [Google Scholar]
  12. Papadaki H., Finkelstein S. D., Kounelis S., Bakker A., Swalsky P. A., Kapadia S. B. The role of p53 mutation and protein expression in primary and recurrent adenoid cystic carcinoma. Hum Pathol. 1996 Jun;27(6):567–572. doi: 10.1016/s0046-8177(96)90163-x. [DOI] [PubMed] [Google Scholar]
  13. Press M. F., Pike M. C., Hung G., Zhou J. Y., Ma Y., George J., Dietz-Band J., James W., Slamon D. J., Batsakis J. G. Amplification and overexpression of HER-2/neu in carcinomas of the salivary gland: correlation with poor prognosis. Cancer Res. 1994 Nov 1;54(21):5675–5682. [PubMed] [Google Scholar]
  14. Rosa J. C., Fonseca I., Félix A., Soares J. Immunohistochemical study of c-erbB-2 expression in carcinoma ex-pleomorphic adenoma. Histopathology. 1996 Mar;28(3):247–252. doi: 10.1046/j.1365-2559.1996.d01-424.x. [DOI] [PubMed] [Google Scholar]
  15. Seifert G. Histopathology of malignant salivary gland tumours. Eur J Cancer B Oral Oncol. 1992 Jul;28B(1):49–56. doi: 10.1016/0964-1955(92)90013-q. [DOI] [PubMed] [Google Scholar]
  16. Shrestha P., Huang J. W., Tsuji T., Shinozaki F., Maeda K., Sasaki K., Ueno K., Yamada K., Mori M. Rare expression of the c-erbB-2 oncoprotein in salivary gland tumors: an immunohistochemical study. J Oral Pathol Med. 1992 Nov;21(10):477–480. doi: 10.1111/j.1600-0714.1992.tb00978.x. [DOI] [PubMed] [Google Scholar]
  17. Soini Y., Kamel D., Nuorva K., Lane D. P., Vähäkangas K., Päkkö P. Low p53 protein expression in salivary gland tumours compared with lung carcinomas. Virchows Arch A Pathol Anat Histopathol. 1992;421(5):415–420. doi: 10.1007/BF01606914. [DOI] [PubMed] [Google Scholar]
  18. Sugano S., Mukai K., Tsuda H., Hirohashi S., Furuya S., Shimosato Y., Ebihara S., Takeyama I. Immunohistochemical study of c-erbB-2 oncoprotein overexpression in human major salivary gland carcinoma: an indicator of aggressiveness. Laryngoscope. 1992 Aug;102(8):923–927. doi: 10.1288/00005537-199208000-00013. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Clinical Pathology are provided here courtesy of BMJ Publishing Group

RESOURCES